Gilje Patrik, Gidlöf Olof, Rundgren Malin, Cronberg Tobias, Al-Mashat Mariam, Olde Björn, Friberg Hans, Erlinge David
Crit Care. 2014 Mar 3;18(2):R40. doi: 10.1186/cc13753.
Early prognostication after successful cardiopulmonary resuscitation is difficult, and there is a need for novel methods to estimate the extent of brain injury and predict outcome. In this study, we evaluated the impact of the cardiac arrest syndrome on the plasma levels of selected tissue-specific microRNAs (miRNAs) and assessed their ability to prognosticate death and neurological disability.
We included 65 patients treated with hypothermia after cardiac arrest in the study. Blood samples were obtained at 24 hours and at 48 hours. For miRNA-screening purposes, custom quantitative polymerase chain reaction (qPCR) panels were first used. Thereafter individual miRNAs were assessed at 48 hours with qPCR. miRNAs that successfully predicted prognosis at 48 hours were further analysed at 24 hours. Outcomes were measured according to the Cerebral Performance Category (CPC) score at 6 months after cardiac arrest and stratified into good (CPC score 1 or 2) or poor (CPC scores 3 to 5).
At 48 hours, miR-146a, miR-122, miR-208b, miR-21, miR-9 and miR-128 did not differ between the good and poor neurological outcome groups. In contrast, miR-124 was significantly elevated in patients with poor outcomes compared with those with favourable outcomes (P < 0.0001) at 24 hours and 48 hours after cardiac arrest. Analysis of receiver operating characteristic curves at 24 and 48 hours after cardiac arrest showed areas under the curve of 0.87 (95% confidence interval (CI) = 0.79 to 0.96) and 0.89 (95% CI = 0.80 to 0.97), respectively.
The brain-enriched miRNA miR-124 is a promising novel biomarker for prediction of neurological prognosis following cardiac arrest.
成功进行心肺复苏后的早期预后评估具有挑战性,因此需要新的方法来评估脑损伤程度并预测预后。在本研究中,我们评估了心脏骤停综合征对特定组织特异性微小RNA(miRNA)血浆水平的影响,并评估了它们预测死亡和神经功能障碍的能力。
我们纳入了65例心脏骤停后接受低温治疗的患者。在24小时和48小时采集血样。首先使用定制的定量聚合酶链反应(qPCR)检测板进行miRNA筛查。此后,在48小时时用qPCR对单个miRNA进行评估。在48小时成功预测预后的miRNA在24小时时进一步分析。根据心脏骤停后6个月的脑功能分类(CPC)评分来衡量预后,并分为良好(CPC评分为1或2)或不良(CPC评分为3至5)。
在48小时时,miR-146a、miR-122、miR-208b、miR-21、miR-9和miR-128在神经功能预后良好和不良的两组之间没有差异。相比之下,在心脏骤停后24小时和48小时,预后不良的患者中miR-124水平明显高于预后良好的患者(P < 0.0001)。心脏骤停后24小时和48小时的受试者工作特征曲线分析显示,曲线下面积分别为0.87(95%置信区间(CI)=0.79至0.96)和0.89(95%CI=0.80至0.97)。
脑富集miRNA miR-124是预测心脏骤停后神经功能预后的一种有前景的新型生物标志物。